Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

Segment Information (Tables)

3 Months Ended

Sep. 30, 2023

Schedule of financial information by reportable segment

The following is financial information relating to the Company's reportable segments (in thousands):


	Quarter Ended
	September 30,
	2023		2022
Net sales:
Protein Sciences	$	204,655	$	199,949
Diagnostics and Genomics		72,797		69,904
Intersegment		(517)		(198)
Consolidated net sales	$	276,935	$	269,655

Operating income:
Protein Sciences	$	88,361	$	85,942
Diagnostics and Genomics		527		8,638
Segment operating income	$	88,888	$	94,580
Costs recognized on sale of acquired inventory		(181)		(300)
Amortization of intangibles		(19,851)		(19,283)
Impact of partially-owned consolidated subsidiaries⁽¹⁾		—		647
Acquisition related expenses and other		588		(297)
Stock based compensation, inclusive of employer taxes		(11,494)		(15,458)
Restructuring costs		(89)		(2,170)
Corporate general, selling, and administrative expenses		(1,999)		(1,402)
Consolidated operating income	$	55,862	$	56,317

⁽¹⁾ Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party